562 related articles for article (PubMed ID: 14747572)
21. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
Luo K; Liu B; Xiao Z; Yu Y; Yu X; Gorelick R; Yu XF
J Virol; 2004 Nov; 78(21):11841-52. PubMed ID: 15479826
[TBL] [Abstract][Full Text] [Related]
22. Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G.
Ribeiro AC; Maia e Silva A; Santa-Marta M; Pombo A; Moniz-Pereira J; Goncalves J; Barahona I
J Virol; 2005 Jan; 79(2):823-33. PubMed ID: 15613310
[TBL] [Abstract][Full Text] [Related]
23. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
Sheehy AM; Gaddis NC; Choi JD; Malim MH
Nature; 2002 Aug; 418(6898):646-50. PubMed ID: 12167863
[TBL] [Abstract][Full Text] [Related]
24. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
Schäfer A; Bogerd HP; Cullen BR
Virology; 2004 Oct; 328(2):163-8. PubMed ID: 15464836
[TBL] [Abstract][Full Text] [Related]
25. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
[TBL] [Abstract][Full Text] [Related]
26. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.
Huthoff H; Malim MH
J Virol; 2007 Apr; 81(8):3807-15. PubMed ID: 17267497
[TBL] [Abstract][Full Text] [Related]
27. DNAJB8 facilitates autophagic-lysosomal degradation of viral Vif protein and restricts HIV-1 virion infectivity by rescuing APOBEC3G expression in host cells.
Chand K; Barman MK; Ghosh P; Mitra D
FASEB J; 2023 Mar; 37(3):e22793. PubMed ID: 36723955
[TBL] [Abstract][Full Text] [Related]
28. Recent insights into HIV-1 Vif.
Navarro F; Landau NR
Curr Opin Immunol; 2004 Aug; 16(4):477-82. PubMed ID: 15245742
[TBL] [Abstract][Full Text] [Related]
29. Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells.
Takeuchi H; Buckler-White A; Goila-Gaur R; Miyagi E; Khan MA; Opi S; Kao S; Sokolskaja E; Pertel T; Luban J; Strebel K
J Virol; 2007 Aug; 81(15):8080-90. PubMed ID: 17522232
[TBL] [Abstract][Full Text] [Related]
30. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action.
Mangeat B; Turelli P; Liao S; Trono D
J Biol Chem; 2004 Apr; 279(15):14481-3. PubMed ID: 14966139
[TBL] [Abstract][Full Text] [Related]
31. Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization.
Wichroski MJ; Ichiyama K; Rana TM
J Biol Chem; 2005 Mar; 280(9):8387-96. PubMed ID: 15537645
[TBL] [Abstract][Full Text] [Related]
32. [HIV-1, a very Vif virus].
Schwartz O
Med Sci (Paris); 2004 Feb; 20(2):139-41. PubMed ID: 14997428
[No Abstract] [Full Text] [Related]
33. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
Schröfelbauer B; Chen D; Landau NR
Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3927-32. PubMed ID: 14978281
[TBL] [Abstract][Full Text] [Related]
34. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection.
Jäger S; Kim DY; Hultquist JF; Shindo K; LaRue RS; Kwon E; Li M; Anderson BD; Yen L; Stanley D; Mahon C; Kane J; Franks-Skiba K; Cimermancic P; Burlingame A; Sali A; Craik CS; Harris RS; Gross JD; Krogan NJ
Nature; 2011 Dec; 481(7381):371-5. PubMed ID: 22190037
[TBL] [Abstract][Full Text] [Related]
35. Rapid evolution of primate antiviral enzyme APOBEC3G.
Zhang J; Webb DM
Hum Mol Genet; 2004 Aug; 13(16):1785-91. PubMed ID: 15198990
[TBL] [Abstract][Full Text] [Related]
36. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
Zhang H; Yang B; Pomerantz RJ; Zhang C; Arunachalam SC; Gao L
Nature; 2003 Jul; 424(6944):94-8. PubMed ID: 12808465
[TBL] [Abstract][Full Text] [Related]
37. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
Soros VB; Yonemoto W; Greene WC
PLoS Pathog; 2007 Feb; 3(2):e15. PubMed ID: 17291161
[TBL] [Abstract][Full Text] [Related]
38. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function.
Kobayashi M; Takaori-Kondo A; Miyauchi Y; Iwai K; Uchiyama T
J Biol Chem; 2005 May; 280(19):18573-8. PubMed ID: 15781449
[TBL] [Abstract][Full Text] [Related]
39. Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more?
Carr JM; Davis AJ; Feng F; Burrell CJ; Li P
Curr Drug Targets; 2006 Dec; 7(12):1583-93. PubMed ID: 17168833
[TBL] [Abstract][Full Text] [Related]
40. The tyrosine kinases Fyn and Hck favor the recruitment of tyrosine-phosphorylated APOBEC3G into vif-defective HIV-1 particles.
Douaisi M; Dussart S; Courcoul M; Bessou G; Lerner EC; Decroly E; Vigne R
Biochem Biophys Res Commun; 2005 Apr; 329(3):917-24. PubMed ID: 15752743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
